Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: A cost-effectiveness analysis for the United States

PharmacoEconomics

Volumn 31, Issue 5, 2013, Pages 427-444

  Simpson, Kit N ^a   Pei, Pamela P ^b,c   Möller, Jörgen ^c   Baran, Robert W ^d   Dietz, Birgitta ^e   Woodward, William ^d   Migliaccio Walle, Kristen ^b,c   Caro, J Jaime ^c,f  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNITED BIOSOURCE CORPORATION   (United States)

^d ABBOTT LABORATORIES   (United States)

^e ABBOTT GMBH AND CO KG   (Germany)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE HEPATITIS; ACUTE KIDNEY FAILURE; ADHESION; ADULT; ANTIVIRAL THERAPY; ARTICLE; BRAIN HEMORRHAGE; CD4 LYMPHOCYTE COUNT; CHOLELITHIASIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE COURSE; DRUG COST; HEADACHE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; LIPODYSTROPHY; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROLITHIASIS; PAIN; PANCREATITIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RASH; SIMULATION; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; VIRUS LOAD; VIRUS MUTATION; VOMITING;

ADULT; ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; MODELS, ECONOMIC; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; RITONAVIR; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84877981087     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0048-3     Document Type: Article

References (78)

1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725-33.
2. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;279(12):930-7.
3. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-60.
4. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194(1):11-9.
5. Braithwaite RS, Justice AC, Chang C-CH, Fusco JS, Raffanti SR, Wong JB, et al. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med. 2005;118(8):890-8.
6. Centers for Disease Control and Prevention (CDC). HIV United States Fact Sheet: HIV in the United States at a glance. Atlanta: CDC; 2013. http://www.cdc.gov/hiv/resources/factsheets/PDF/stats-basics-factsheet.pdf. Accessed 20 Mar 2013.
7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Updated 12 Feb 2013. http://aidsinfo.nih.gov/contentfiles/lvguidelines/ adultandadolescentgl.pdf. Accessed 10 Mar 2013.
8. Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22(12):1389-97.
9. Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard P-M, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23(13):1679-88.
10. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA. 1993;270(4):474-8.
11. Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, del Rio C, Kamimoto L, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr. 2006;43(4):451-7.
12. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44(11):990-7.
13. Simpson KN, Rajagopalan R, Dietz B. Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir + ritonavir regimens in the CASTLE study. Adv Ther. 2009;26(2):185-93.
14. Simpson KN. Economic modeling of HIV treatments. Curr Opin HIV AIDS. 2010;5(3):242-8.
15. Caro JJ, Moller J, Getsios D. Discrete event simulation: the preferred technique for health economic evaluations? Value Health. 2010;13(8):1056-60.
16. Karnon J, Stahl J, Alan B, et al. Modeling using discrete event simulation: a report of the ISPOR-SMDM modeling good research practices task force working group 4. Value Health. 2012;15(6):821-7.
17. Antiretroviral Cohort Collaboration (ART-CC). Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. JAIDS. 2009;52:357-63.
18. Molina J-M, Podsadecki TJ, Johnson MA, Wilkin A, Domingo P, Myers R, et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retrovir. 2007;23(12):1505-14.
19. Murphy RL, da Silva BA, Hicks CB, Eron JJ, Gulick RM, Thompson MA, et al. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials. 2008;9(1):1-10.
20. Gathe J, daSilva B, Loutfy M, et al. Study M05-730 primary efficacy results at week 48: phase 3, randomized, open-label study of lopinavir-ritonavir (LPV/r) tablets once-daily (OD) vs. twice-daily (BID), co-administered with tenofovir (TDF) plus emtricitabine (FTC) in antiretroviral naïve (ARV) HIV-1-infected subjects. In: 15th Conference on retroviruses and opportunistic infections (CROI), Boston, MA; 3-6 Feb 2008.
21. Kaletra package insert. Revision 3/2010. North Chicago: AbbVie Inc.; 2010. http://www.rxabbott.com/pdf/kaletratabpi.pdf. Accessed 15 Jul 2011.
22. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, D'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17(8):1179-93.
23. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30.
24. King MS, Brun SC, Kempf DJ. Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J Infect Dis. 2002;191(12):2046-52.
25. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34(8):1115-21.
26. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002;16(2):201-7.
27. Gonzalez de Requena D, Bonora S, Garazzino S, Sciandra M, D'Avolio A, Raiteri R, et al. Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrob Agents Chemother. 2005;49(9):3966-9.
28. Nelson M, Girard PM, DeMasi R, et al. Adherence to darunavir/ritonavir and lopinavir/ritonavir in treatment-naïve, HIV-infected patients in ARTEMIS: 96 week data. In: 15th Annual conference of the British HIV Association, London; 8-9 Oct 2009.
29. National Center for Infectious Diseases Division of HIV/AIDS. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Atlanta: CDC; 1992. http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm. Accessed 20 Jul 2011.
30. Ghani AC, de Wolf F, Ferguson NM, Donnelly CA, Coutinho R, Miedema F, et al. Surrogate markers for disease progression in treated HIV infection. J Acquir Immune Defic Syndr. 2001;28(3):226-31.
31. Ghani AC, Henley WE, Donnelly CA, Mayer S, Anderson RM. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases. AIDS. 2001;15(9):1133-42.
32. Gebo KA, Gallant JE, Keruly JC, Moore RD. Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection. J Acquir Immune Defic Syndr. 2004;36(5):1028-33.
33. Rahim S, Fredrick LM, da Silva BA, Bernstein B, King MS. Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naive subjects screening for two clinical trials in North America and Western Europe. HIV Clin Trials. 2009;10(2):94-103.
34. Hill A, Pulido F, Arribas J, Moecklinghoff C. Prevalence of IAS-USA PI mutations during episodes of viremia in the MONET trial of darunavir/ritonavir, with or without nucleoside analogues. In: 8th European HIV drug resistance workshop, 2010, Sorrento; 17-19 Mar 2010.
35. Cahn P, Fourie J, Grinsztejn B, Hodder S, Molina J-M, Ruxrungtham K, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 2011;25(7):929-39.
36. Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, et al. Long-term (96-week) follow-up of antiretroviral-naive HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. HIV Med. 2010;11(2):137-42.
37. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121(1 Part 2):293-8.
38. AnalySource® Online. http://www.firstdatabank.com/Products/ analysource.aspx ? Accessed 20 May 2011 (by subscription only).
39. Andrulis DP, Weslowski VB, Hintz E, Spolarich AW. Comparisons of hospital care for patients with AIDS and other HIV-related conditions. JAMA. 1992;267(18):2482-6.
40. Caro JJ, Stillman IO, Danel A, Getsios D, McEwan P. Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model. J Med Econ. 2007;10:239-54.
41. Huang JS, Becerra K, Fernandez S, Lee D, Mathews WC. The impact of HIV-associated lipodystrophy on healthcare utilization and costs. AIDS Res Ther. 2008;5:14.
42. US Bureau of Labor Statistics. Consumer price index, medical care. Washington, DC: US Bureau of Labor Statistics. Series Id: CUUR0000SAM2 Not Seasonally Adjusted. Area: U.S. city average. Item: Medical care services. Base Period: 1982-84=100. http://data.bls.gov/. Accessed 8 May 2011.
43. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095-108.
44. Moore RD, Chaisson RE. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16(1):15-21.
45. Simpson KN, Dietz B, Baran RW, Garren KW, Riddler SA, Bhor M, et al. Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data. Cost Eff Resour Alloc. 2011;9:5.
46. Bayoumi AM, Redelmeier DA. Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. AIDS. 1998;12(12):1503-12.
47. Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force working group 7. Value Health. 2012;15:845-50.
48. Kaplan SS, Hicks CB. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection. J Antimicrob Chemother. 2005;56(2):273-6.
49. Hicks C, King MS, Gulick RM, White AC, Eron JJ, Kessler HA, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS. 2004;18(5):775-9.
50. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165-78.
51. Weinstein MC. How much are Americans willing to pay for a quality-adjusted life year? Med Care. 2008;46(4):343-5.
52. Briggs A, Weinstein M, Fenwick E, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Value Health. 2012;32(5):722-32.
53. Glick HA. Sampling uncertainty: what we are doing right and where we are going wrong. In: ISPOR western pharmacoeconomics conference, 2009, Pasadena, CA; 18-20 Mar 2009.
54. Caro J, Briggs A, Siebert U, et al. Modeling good research practices - overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health. 2012;15(6):796-803.
55. Mocroft A, Lundgren JD. Starting highly active antiretroviral therapy: why, when and response to HAART. J Antimicrob Chemother. 2004;54(1):10-3.
56. Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010;11(3):133-44.
57. Mauskopf J, Brogan A, Martin S, Smets E. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. Pharmacoeconomics. 2010;28(Suppl 1):83-105.
58. Moeremans K, Annemans L, Lothgren M, Allegri G, Wyffels V, Hemmet L, et al. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics. 2010;28(Suppl 1):107-28.
59. Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics. 2010;28(Suppl 1):147-67.
60. Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-3. Value Health. 2012;15(6):812-20.
61. Roberts M, Russel L, Paltiel AD, et al. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-2. Value Health. 2012;15(6):804-11.
62. Stanford University. HIV Drug Resistance Database. HIVdb Program: genotypic resistance interpretation algorithm. Stanford: HIVDB; 2011. http://sierra2.stanford.edu/sierra/servlet/JSierra. Accessed 17 Feb 2011.
63. Barros ZM, de Alencar Ximenes RA, Miranda-Filho DB, de Albuquerque MdFPM, Melo HRL, Carvalho EH, et al. Comparison between the Framingham and prospective cardiovascular of Munster scores for risk assessment of coronary heart disease in human immunodeficiency virus-positive patients in Pernambuco, Brazil. Metab Syndr Relat Disord. 2010;8(6):489-97.
64. Falcone EL, Mangili A, Skinner S, Alam A, Polak JF, Wanke CA. Framingham risk score and early markers of atherosclerosis in a cohort of adults infected with HIV. Antivir Ther. 2011;16(1):1-8.
65. Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte ADA, De Wit S, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17(5):491-501.
66. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20(5):711-8.
67. Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370(9581):49-58.
68. Dragsted UB, et al. A phase IV randomised, open-label, multicentre trial to evaluate safety and efficacy of indinavir/ritonavir (800/100 mg BID) vs. saquinavir/ritonavir (1000/100 mg BID) in adult HIV-1 infection: the MaxCmin 1 trial. In: 8th ECCATH, Athens; 29-31 Oct 2001.
69. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370(9581):29-38.
70. Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010;50(4):605-12.
71. Lexiva package insert. http://viivhealthcare.com/~/media/Files/G/ GlaxoSmithKline-Plc/pdfs/us-lexiva.pdf. Accessed 1 Apr 2011.
72. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368(9534):466-75.
73. Lalezari JP, Henry K, O'Hearn M, Montaner JSG, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348(22):2175-85.
74. Trotta MP, Cozzi-Lepri A, Ammassari A, Vecchiet J, Cassola G, Caramello P, et al. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures. Clin Infect Dis. 2010;51(4):456-64.
75. Simpson KN, Luo MP, Chumney E, Sun E, Brun S, Ashraf T. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004;5(5):294-304.
76. Simpson K. Event data for South Carolina Medicaid patients from 2002 and 2003. Columbia: S.C. Budget and Control Board, Office of Research & Statistics; 2005.
77. - 2007 and 2008 HCUP state inpatient data for CA, FL, MA, MD, NJ, WA. State Inpatient Databases (SID), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality. http://www.hcup-us.ahrq.gov/db/ state/siddbdocumentation.jsp. Accessed 21 Mar 2013.
78. Health Care Finance Review/2009 Statistical Supplement. http://www.cms.gov/MedicareMedicaidStatSupp/LT/itemdetail.asp?filterType= none&filterByDID=0&sortByDID=2&sortOrder=descending&itemID= CMS1232665&intNumPerPage=10. Accessed 29 Nov 2010.